MaxCyte Balance Sheet Health

Financial Health criteria checks 6/6

MaxCyte has a total shareholder equity of $213.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $248.6M and $35.3M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$153.83m
EquityUS$213.30m
Total liabilitiesUS$35.31m
Total assetsUS$248.61m

Recent financial health updates

No updates

Recent updates

MaxCyte expands capacity by relocating to new HQ in Maryland

Sep 21

MaxCyte signs strategic platform with LG Chem

Jul 12

MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile

Sep 06

Financial Position Analysis

Short Term Liabilities: MXCT's short term assets ($172.9M) exceed its short term liabilities ($17.6M).

Long Term Liabilities: MXCT's short term assets ($172.9M) exceed its long term liabilities ($17.7M).


Debt to Equity History and Analysis

Debt Level: MXCT is debt free.

Reducing Debt: MXCT has no debt compared to 5 years ago when its debt to equity ratio was 36%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MXCT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: MXCT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 21.3% each year


Discover healthy companies